- Patients
- Clinical Research
- Clinical trials
- REZILIENT2
2024-06-20T09:27:50.318Z
REZILIENT2
REZILIENT2
Lung cancer
An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations
An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations
Trial overview
Clinical Area
Medical Oncology
Disease / Condition
Lung Cancer
Study Phase
IIb
Trial Identifiers